Literature DB >> 1329637

Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery.

M Kinzig1, F Sörgel, B Brismar, C E Nord.   

Abstract

The pharmacokinetics of tazobactam and piperacillin in plasma and different tissues after a 30-min intravenous infusion of 4 g of piperacillin and 0.5 g of tazobactam were investigated in 18 patients who underwent elective colorectal surgery. Serial blood samples were collected for up to 6 h after the initiation of the infusion. The types of tissue collected were fatty tissue, muscle, skin, appendix, and intestinal mucosa (proximal and distal). On the basis of concentrations in plasma, the following pharmacokinetic parameter values were obtained (values are means +/- standard deviations): maximum concentration of drug in serum, tazobactam, 27.9 +/- 7.67 micrograms/ml; piperacillin, 259 +/- 81.8 micrograms/ml; time to maximum concentration of drug in serum, tazobactam, 0.51 +/- 0.03 h; piperacillin, 0.51 +/- 0.03 h; area under the concentration-time curve, tazobactam, 47.6 +/- 13.3 micrograms.h/ml; piperacillin, 361 +/- 80.3 micrograms.h/ml; clearance, tazobactam, 188 +/- 52.3 ml/min; piperacillin, 194 +/- 42.9 ml/min; half-life, tazobactam, 1.42 +/- 0.32 h; piperacillin, 1.27 +/- 0.24 h; apparent volume of distribution, tazobactam, 0.31 +/- 0.07 liter/kg of body weight; piperacillin, 0.29 +/- 0.06 liter/kg; volume of distribution at steady state, tazobactam, 0.28 +/- 0.04 liter/kg; piperacillin, 0.25 +/- 0.05 liter/kg. The concentrations of tazobactam and piperacillin in fatty tissue and muscle tissue were 10 to 13 and 18 to 30% of the levels in plasma, respectively. In skin, the concentrations of piperacillin were 60 to 95% of the levels in plasma, whereas the concentrations of tazobactam in plasma were 49 to 93% of the levels in skin tissue. The mean concentration of tazobactam in the investigated gastrointestinal tissues (appendix, proximal and distal mucosa) exceeded levels in plasma after 1 h, while piperacillin showed a mean penetration into these tissues of 43 and 53%. The mechanisms that can be used to explain the extent of penetration of piperacillin and tazobactam are discussed. Simple diffusion may take place in fatty and muscle tissue, while penetration into skin and gastrointestinal tissue is governed by more complex mechanisms which lead to differences in penetration between piperacillin and tazobactam. For all tissues investigated (except fatty tissue), the time course of the concentrations of both compounds was similar, with a peak in concentration at between 1 and 2 h after the start of infusion followed by a decline of concentrations that were almost parallel to the curves of the drug concentrations in plasma. In plasma and in all investigated tissues, piperacillin as well as tazobactam reached or exceeded the concentrations found to be effective in vitro.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1329637      PMCID: PMC192425          DOI: 10.1128/AAC.36.9.1997

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Protection of piperacillin and ticarcillin from beta-lactamase hydrolysis by tazobactam (YTR-830) and clavulanic acid.

Authors:  J M Diver; D Thornber; R Wise
Journal:  J Antimicrob Chemother       Date:  1989-07       Impact factor: 5.790

2.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

3.  Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia.

Authors:  J J Schentag
Journal:  Scand J Infect Dis Suppl       Date:  1990

Review 4.  Human pharmacodynamics of beta-lactams, aminoglycosides and their combination.

Authors:  G L Drusano
Journal:  Scand J Infect Dis Suppl       Date:  1990

5.  Antibacterial activity of piperacillin and tazobactam against beta-lactamase-producing clinical isolates.

Authors:  W Cullmann; M Stieglitz
Journal:  Chemotherapy       Date:  1990       Impact factor: 2.544

6.  Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).

Authors:  R N Jones; A L Barry
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Nov-Dec       Impact factor: 2.803

7.  Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.

Authors:  N A Kuck; N V Jacobus; P J Petersen; W J Weiss; R T Testa
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

8.  High-performance liquid chromatography analysis of mezlocillin, piperacillin, their degradation products, and of ioxitalamic acid in plasma and urine of healthy volunteers.

Authors:  F Kees; K G Naber; B Bartoschik-Wich; P Stockmann; G P Meyer; H Grobecker
Journal:  Arzneimittelforschung       Date:  1985

9.  Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin.

Authors:  R Wise; M Logan; M Cooper; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 10.  Piperacillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; D M Richards; R N Brogden; R C Heel
Journal:  Drugs       Date:  1984-11       Impact factor: 9.546

View more
  27 in total

1.  Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.

Authors:  N Patel; M H Scheetz; G L Drusano; T P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2009-10-26       Impact factor: 5.191

2.  A Population Pharmacokinetics and Pharmacodynamic Approach To Optimize Tazobactam Activity in Critically Ill Patients.

Authors:  Shamir N Kalaria; Mathangi Gopalakrishnan; Emily L Heil
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

3.  Piperacillin-tazobactam penetration into human pancreatic juice.

Authors:  Elisa Bertazzoni Minelli; Anna Benini; Luigina Franco; Claudio Bassi; Paolo Pederzoli
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

4.  Penetration of piperacillin-tazobactam into bronchial secretions after multiple doses to intensive care patients.

Authors:  F Jehl; C Muller-Serieys; V de Larminat; H Monteil; E Bergogne-Berezin
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

5.  Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients.

Authors:  R Nau; M Kinzig-Schippers; F Sörgel; S Schinschke; R Rössing; C Müller; H Kolenda; H W Prange
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  Pharmacodynamic model for β-lactam regimens used in surgical prophylaxis: model-based evaluation of standard dosing regimens.

Authors:  XiangQing Song; MingHui Long
Journal:  Int J Clin Pharm       Date:  2018-08-16

7.  Pharmacokinetics of Piperacillin in Critically Ill Australian Indigenous Patients with Severe Sepsis.

Authors:  Danny Tsai; Penelope Stewart; Rajendra Goud; Stephen Gourley; Saliya Hewagama; Sushena Krishnaswamy; Steven C Wallis; Jeffrey Lipman; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

8.  Neutralization of antimicrobial substances in new BacT/Alert FA and FN Plus blood culture bottles.

Authors:  Dieter Mitteregger; Wolfgang Barousch; Marion Nehr; Michael Kundi; Markus Zeitlinger; Athanasios Makristathis; Alexander M Hirschl
Journal:  J Clin Microbiol       Date:  2013-03-13       Impact factor: 5.948

9.  Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group.

Authors:  J S Tan; R M Wishnow; D A Talan; F P Duncanson; C W Norden
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

10.  Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children.

Authors:  M D Reed; J Goldfarb; T S Yamashita; E Lemon; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.